Generalisierte pustulöse Psoriasis: Es tut sich was!

Risankizumab, a humanized immunoglobin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit, is approved in Japan treat numerous indications, including generalized pustular psoriasis (GPP) and erythrodermic (EP). Both GPP EP are severe forms of have limited treatment options. In IMMspire (A Study Assess Efficacy Safety Two Different Dose Regimens Risankizumab Administered Subcutaneously Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis) (NCT03022045), phase 3, randomized, multicenter study Japan, we evaluated the efficacy safety risankizumab for adults with EP. Patients were randomized (1:1) receive open-label 75 mg 150 at weeks 0 4 every 12 thereafter through week 160. The primary end point was clinical response 16. Other points included response, ≥90% improvement from baseline Area Severity Index (PASI 90) Dermatology Life Quality 1 (DLQI 0/1) 180 (last follow-up visit). assessed throughout. A total 17 patients (eight nine EP) enrolled. All achieved Among continuing treatment, achievement PASI 90 DLQI 0/1 generally sustained throughout treatment. profile remained consistent profiles noted previous studies. demonstrated clinically meaningful 16, durable favorable long-term